Journal
EXPERIMENTAL DERMATOLOGY
Volume 23, Issue 11, Pages 804-806Publisher
WILEY-BLACKWELL
DOI: 10.1111/exd.12541
Keywords
psoriasis; IL-17; Th17 cells; secukinumab; ixekizumab; brodalumab
Categories
Funding
- AbbVie
- BiogenIdec
- Janssen
- Lilly
- MSD
- Novartis
Ask authors/readers for more resources
Psoriasis is an instructive example highlighting our growing knowledge about pathophysiological functions of interleukin (IL)-17. IL-17A is the predominant isoform implicated in key pathogenic features in this and other chronic inflammatory disorders. Several monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) or its IL-17RC/RA receptor (brodalumab) are currently in late stages of clinical development, where they have shown impressive efficacy. While the eponymous IL-17 has been thought to originate primarily from T helper (Th)17 cells, more recent investigations by several groups suggest that other cell types in psoriatic lesions, such as neutrophils and mast cells, are rich sources of IL-17, thus presumably contributing to the disease process to an as yet underestimated extent. This recent paradigm shift provides a plausible explanation for the rapid and strong efficacy of the novel compounds targeting IL-17 functions in psoriasis and other inflammatory disorders, and provide a more comprehensive view on the complex cytokine network in these conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available